Novartis PM onboarding first 90 days what to expect 2026

Title: Novartis PM Onboarding First 90 Days What to Expect 2026

TL;DR

The first 90 days as a Product Manager at Novartis are not about launching products—they’re about learning the therapeutic area, aligning with compliance constraints, and building trust with medical affairs. Most PMs misread the onboarding pace, assuming execution is the goal, when influence without authority is the real KPI. Your success hinges not on speed, but on how quickly you reframe commercial ambition within Novartis’ risk-averse, science-led culture.

Who This Is For

This is for product managers who’ve accepted or are starting a PM role at Novartis in 2026, including those transitioning from tech, startups, or other pharma companies. It’s especially relevant if you lack deep pharma experience. You’re likely overestimating your autonomy and underestimating the weight of governance. This guide reflects real onboarding patterns from cardiovascular, oncology, and generics divisions in 2024–2025.

What does the Novartis PM onboarding timeline look like in the first 90 days?

The first 90 days follow a rigid three-phase structure: Days 1–30 are compliance and domain immersion, Days 31–60 are stakeholder mapping and pipeline literacy, Days 61–90 are controlled contribution via cross-functional task forces. No PM ships independent work before Day 60.

In Q2 2025, a new oncology PM in Basel pushed for early campaign ideation during week three. The hiring manager shut it down in a 1:1: “We don’t brainstorm here. We validate.” That moment crystallized a core norm: creativity is welcome, but only after alignment. At Novartis, permission precedes initiative.

Not innovation, but controlled iteration is rewarded. Not autonomy, but integration is measured. Not speed to market, but speed to compliance is the hidden metric.

You’ll spend 40% of your time in training—GxP, promotional compliance, data privacy—non-negotiable for commercial roles. Another 30% is shadowing: MSLs, market access specialists, regulatory affairs. The remaining 30% is team meetings where you’re expected to listen, not lead.

By Day 45, you’ll have your first stakeholder alignment checkpoint with medical affairs. Fail this, and your influence stalls for months. Pass it, and you’re invited to draft inputs for a brand steering committee—still not a decision-maker, but now in the room.

How does Novartis’ culture impact a new PM’s first 90 days?

Culture at Novartis is not collaborative by default—it’s consensus-dependent. Your ability to navigate committees, not your product sense, determines early momentum. In a debrief last year, a hiring manager said, “She had strong GTM instincts, but she didn’t wait for medical legal review. That’s a red flag here.”

New PMs from Amazon or Google often struggle because they’re used to launching and learning. At Novartis, you learn, align, and then—maybe—launch. The feedback loop is longer, and mistakes are less about revenue loss, more about reputational risk.

In 2024, a PM in the US launched a patient support program with digital nudges. The concept was sound, but medical affairs hadn’t reviewed the copy. The program was paused for six weeks. The PM wasn’t fired, but was reassigned to a low-profile asset. That case is now taught in onboarding as a cultural cautionary tale.

Not urgency, but precision is valued. Not ownership, but stewardship is expected. Not disruption, but evolution is permitted.

You will attend Brand Strategic Planning (BSP) meetings from Day 21. But you won’t present. You’ll take notes. Your role is to absorb how decisions are justified—not by TAM or funnel metrics, but by clinical data, payer dynamics, and risk mitigation.

One neurology PM described it as “watching chess played in slow motion.” You’re not expected to move pieces. You’re expected to learn the rules—many of which aren’t written down.

What training programs do new Novartis PMs complete in the first 90 days?

New PMs complete seven mandatory training modules by Day 30, tracked in the internal LMS. These include GxP Basics (4 hours), Promotional Compliance (6 hours), Data Privacy (3 hours), Patient Safety Reporting (2 hours), Brand Governance (4 hours), Market Access Fundamentals (5 hours), and Inclusive Leadership (3 hours). Completion is non-negotiable; delay impacts bonus eligibility.

In 2025, a PM in the generics division missed the Brand Governance deadline by two days. The hiring manager noted it in their 30-day review: “Lack of urgency on compliance.” That comment followed them into the first performance calibration.

These trainings aren’t formalities—they form the baseline for all commercial decisions. When you propose a campaign, the reviewer doesn’t ask “Will it convert?” They ask “Is this consistent with the monograph and aligned with medical affairs?”

Not knowledge, but demonstrated adherence is assessed. Not curiosity, but compliance is monitored. Not speed, but accuracy is rewarded.

You’ll also be assigned a “buddy”—usually a PM with 2+ years tenure. But don’t expect mentorship. Their role is logistical, not developmental. They’ll help you book meeting rooms and navigate SAP, not coach you on influence.

By Day 60, you’ll attend the Novartis Commercial Academy—a two-day immersive on portfolio strategy and lifecycle management. It’s where most PMs start to connect their role to enterprise goals. But it’s also where the hierarchy becomes visible: medical leads sit at the head table, commercial leads to the side.

How are goals set for PMs during onboarding?

Goals in the first 90 days are not outcome-based—they’re behavior-based. You won’t have KPIs for revenue or adoption. Instead, you’ll be evaluated on stakeholder engagement frequency, training completion, and draft inputs submitted to brand teams.

In 2024, the performance template for new PMs included: “Attend 10 cross-functional meetings with documented takeaways,” “Submit 3 approved inputs to brand strategy,” and “Complete all compliance training by Day 30.” No mention of growth or innovation.

A hiring manager in oncology told me: “We don’t measure what they ship. We measure how they listen.”

By Day 45, you’ll have a “Readiness Review” with your manager and HR. It’s not a promotion—it’s a checkpoint. The three criteria: cultural fit, compliance adherence, and stakeholder feedback. Medical affairs’ input carries 50% weight.

Not impact, but integration is measured. Not results, but process is tracked. Not vision, but alignment is scored.

If you’re strong, you’ll be invited to draft a section of the annual brand plan by Day 75. But it will be reviewed by legal, medical, market access, and HEOR before approval. Your name won’t appear on the final document. That’s normal.

Your manager may give you a small pilot—say, optimizing patient journey touchpoints in one region. But even then, the design must be pre-vetted. Execution is yours. Ownership is shared.

How should I prepare before my first day as a PM at Novartis?

Prepare by studying the asset, not the role. In your first 30 days, you’ll be expected to recite primary endpoints from phase 3 trials, payer coverage rates, and unmet needs in the therapeutic area. Fluency in clinical data is your onboarding currency.

In 2025, a new PM in cardiovascular was asked during their second team meeting to explain the hazard ratio in the latest outcome study. They hesitated. That hesitation was noted. Two weeks later, their onboarding plan was revised to include weekly medical deep dives.

Not business acumen, but scientific literacy is tested early. Not market analysis, but clinical context is expected. Not competitive positioning, but trial design knowledge is respected.

You should also map the organizational chart of your brand team—especially medical affairs, regulatory, and market access. Learn the names, roles, and reporting lines. At Novartis, power is not always in the title.

Read the latest Brand Strategic Plan (BSP) for your product. If you can’t access it, ask your hiring manager during pre-start calls. One PM in 2024 did this and was invited to a prep call with medical affairs before Day 1. That gave them a six-week advantage.

Download and study the product monograph. Know the contraindications, adverse events, and approved indications cold. Your first feedback will likely come from medical affairs questioning your understanding of safety data.

Preparation Checklist

Complete all pre-onboarding paperwork within 48 hours of offer acceptance—delays trigger HR flags
Study the latest phase 3 trial results for your product; be ready to discuss endpoints on Day 5
Memorize the product monograph, especially safety and dosing sections
Map the key stakeholders: medical lead, market access lead, regulatory affairs, HEOR
Work through a structured preparation system (the PM Interview Playbook covers pharma PM onboarding with real debrief examples from Novartis and Roche)
Prepare 3 informed questions about unmet needs in the therapeutic area—bring them to your first 1:1
Schedule an informal coffee chat with your buddy and hiring manager before Day 1

Mistakes to Avoid

BAD: Sending a campaign idea directly to the creative agency without medical legal review

A PM in dermatology did this in 2024. The concept used patient testimonials. It was flagged for violating promotional compliance. The PM was removed from the brand steering committee for six months.

GOOD: Drafting the idea, sharing it with medical affairs first, and incorporating feedback before submission

One respiratory PM did this in 2025. They presented a revised version at the next cross-functional meeting. It was approved in four weeks—slow, but clean.

BAD: Claiming ownership of a product launch in external conversations

In 2024, a new PM said “I’m launching this product” in an internal town hall. The medical lead corrected them live: “We launch together, with data.” The comment spread. The PM was seen as out of step.

GOOD: Using “we” and acknowledging cross-functional partners in all communications

A cardiovascular PM in 2025 consistently said “the team is advancing the launch.” They were praised in their 90-day review for cultural alignment.

BAD: Skipping compliance training to focus on “real work”

One PM delayed GxP training, saying they “already knew the basics.” HR escalated it. Their bonus was pro-rated.

GOOD: Treating compliance as core to the job, not overhead

Another PM completed all training by Day 15 and shared a checklist with their cohort. They were nominated for the onboarding ambassador program.

FAQ

What happens if I don’t meet my 90-day onboarding goals at Novartis?

Missing behavior-based goals—like training deadlines or stakeholder engagement—triggers a performance improvement plan. It won’t get you fired, but it will delay your first bonus and limit project access. The bigger risk is reputational: medical affairs and HR share observations. One misstep won’t end your career, but it will slow your momentum for 6–12 months.

Do new PMs get a mentor at Novartis?

No formal mentorship exists in the first 90 days. You get a buddy for logistics, not development. Real mentorship emerges organically, often from medical affairs or senior commercial leads. Seeking it out is expected, but don’t assume it’s provided. The strongest new PMs identify advisors by Day 20 and schedule monthly check-ins without prompting.

Will I have my own product in the first 90 days?

No. You’ll support an existing product or pipeline asset, but you won’t own it. Even if you’re the designated PM, decisions require consensus. Your role is to coordinate inputs, not make calls. True ownership starts at 12–18 months, after you’ve passed multiple governance reviews and earned trust across functions.

Ready to build a real interview prep system?

Get the full PM Interview Prep System →

The book is also available on Amazon Kindle.